11 research outputs found
Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide/calcitriol liposomes in ACPA+ rheumatoid arthritis
BACKGROUND. Antigen-specific regulation of autoimmune disease is a major goal. In seropositive
rheumatoid arthritis (RA), T cell help to autoreactive B cells matures the citrullinated (Cit)
antigen-specific immune response, generating RA-specific V domain glycosylated anti-Cit protein
antibodies (ACPA VDG) before arthritis onset. Low or escalating antigen administration under
“sub-immunogenic” conditions favors tolerance. We explored safety, pharmacokinetics, and
immunological and clinical effects of s.c. DEN-181, comprising liposomes encapsulating self-peptide
collagen II259-273 (CII) and NF-ÎşB inhibitor 1,25-dihydroxycholecalciferol.
METHODS. A double-blind, placebo-controlled, exploratory, single-ascending-dose, phase I trial
assessed the impact of low, medium, and high DEN-181 doses on peripheral blood CII-specific and
bystander Cit64vimentin59-71–specific (Cit-Vim–specific) autoreactive T cell responses, cytokines,
and ACPA in 17 HLA-DRB1*04:01+
or *01:01+
ACPA+
RA patients on methotrexate.
RESULTS. DEN-181 was well tolerated. Relative to placebo and normalized to baseline
values, Cit-Vim–specific T cells decreased in patients administered medium and high doses
of DEN-181. Relative to placebo, percentage of CII-specific programmed cell death 1+
T cells
increased within 28 days of DEN-181. Exploratory analysis in DEN-181–treated patients
suggested improved RA disease activity was associated with expansion of CII-specific and
Cit-Vim–specific T cells; reduction in ACPA VDG, memory B cells, and inflammatory myeloid
populations; and enrichment in CCR7+
and naive T cells. Single-cell sequencing identified T
cell transcripts associated with tolerogenic TCR signaling and exhaustion after low or medium
doses of DEN-181.
CONCLUSION. The safety and immunomodulatory activity of low/medium DEN-181 doses provide
rationale to further assess antigen-specific immunomodulatory therapy in ACPA+
RA
Recommended from our members
High density genetic mapping identifies new susceptibility loci for rheumatoid arthritis
Summary Using the Immunochip custom single nucleotide polymorphism (SNP) array, designed for dense genotyping of 186 genome wide association study (GWAS) confirmed loci we analysed 11,475 rheumatoid arthritis cases of European ancestry and 15,870 controls for 129,464 markers. The data were combined in meta-analysis with GWAS data from additional independent cases (n=2,363) and controls (n=17,872). We identified fourteen novel loci; nine were associated with rheumatoid arthritis overall and 5 specifically in anti-citrillunated peptide antibody positive disease, bringing the number of confirmed European ancestry rheumatoid arthritis loci to 46. We refined the peak of association to a single gene for 19 loci, identified secondary independent effects at six loci and association to low frequency variants (minor allele frequency <0.05) at 4 loci. Bioinformatic analysis of the data generated strong hypotheses for the causal SNP at seven loci. This study illustrates the advantages of dense SNP mapping analysis to inform subsequent functional investigations
Low amounts of bisecting glycans characterize cerebrospinal fluid-borne IgG
Immunoglobulin G (IgG) harbors a conserved N-glycosylation site which is important for its effector functions. Changes in glycosylation of IgG occur in many autoimmune diseases but also in physiological conditions. Therefore, the glycosylation pattern of serum IgG is well characterized. However, limited data is available on the glycosylation pattern of IgG in cerebrospinal fluid (CSF) compared to serum. Here, we report significantly reduced levels of bisected glycans in CSF IgG. Galactosylation and sialylation of IgG4 also differed significantly. Therefore, we propose a common mechanism mediating glycosylation changes of IgG at the transition from serum to CSF in steady state conditions
Surface Ig variable domain glycosylation affects autoantigen binding and acts as threshold for human autoreactive B cell activation
The hallmark autoantibodies in rheumatoid arthritis are characterized by variable domain glycans (VDGs). Their abundant occurrence results from the selective introduction of N-linked glycosylation sites during somatic hypermutation, and their presence is predictive for disease development. However, the functional consequences of VDGs on autoreactive B cells remain elusive. Combining crystallography, glycobiology, and functional B cell assays allowed us to dissect key characteristics of VDGs on human B cell biology. Crystal structures showed that VDGs are positioned in the vicinity of the antigen-binding pocket, and dynamic modeling combined with binding assays elucidated their impact on binding. We found that VDG-expressing B cell receptors stay longer on the B cell surface and that VDGs enhance B cell activation. These results provide a rationale on how the acquisition of VDGs might contribute to the breach of tolerance of autoreactive B cells in a major human autoimmune disease
Surface Ig variable domain glycosylation affects autoantigen binding and acts as threshold for human autoreactive B cell activation
The hallmark autoantibodies in rheumatoid arthritis are characterized by variable domain glycans (VDGs). Their abundant occurrence results from the selective introduction of N-linked glycosylation sites during somatic hypermutation, and their presence is predictive for disease development. However, the functional consequences of VDGs on autoreactive B cells remain elusive. Combining crystallography, glycobiology, and functional B cell assays allowed us to dissect key characteristics of VDGs on human B cell biology. Crystal structures showed that VDGs are positioned in the vicinity of the antigen-binding pocket, and dynamic modeling combined with binding assays elucidated their impact on binding. We found that VDG-expressing B cell receptors stay longer on the B cell surface and that VDGs enhance B cell activation. These results provide a rationale on how the acquisition of VDGs might contribute to the breach of tolerance of autoreactive B cells in a major human autoimmune disease
A novel method for high-throughput detection and quantification of neutrophil extracellular traps reveals ROS-independent NET release with immune complexes
Gene-Gene and Gene-Environment Interactions Involving HLA-DRB1, PTPN22, and Smoking in Two Subsets of Rheumatoid Arthritis
Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice
Differences in IgG autoantibody Fab glycosylation across autoimmune diseases.
Background: Increased prevalence of autoantibody Fab glycosylation has been demonstrated for several autoimmune diseases. Objectives: To study whether elevated Fab glycosylation is a common feature of autoimmunity, this study investigated Fab glycosylation levels on serum IgG and its subclasses for autoantibodies associated with a range of different B cell–mediated autoimmune diseases, including rheumatoid arthritis, myasthenia gravis subtypes, pemphigus vulgaris, antineutrophil cytoplasmic antibody–associated vasculitis, systemic lupus erythematosus, anti–glomerular basement membrane glomerulonephritis, thrombotic thrombocytopenic purpura, and Guillain-Barré syndrome. Methods: The level of Fab glycosylated IgG antibodies was assessed by lectin affinity chromatography and autoantigen-specific immunoassays. Results: In 6 of 10 autoantibody responses, in 5 of 8 diseases, the investigators found increased levels of Fab glycosylation on IgG autoantibodies that varied from 86% in rheumatoid arthritis to 26% in systemic lupus erythematosus. Elevated autoantibody Fab glycosylation was not restricted to IgG4, which is known to be prone to Fab glycosylation, but was also present in IgG1. When autoimmune diseases with a chronic disease course were compared with more acute autoimmune illnesses, increased Fab glycosylation was restricted to the chronic diseases. As a proxy for chronic autoantigen exposure, the investigators determined Fab glycosylation levels on antibodies to common latent herpes viruses, as well as to glycoprotein 120 in individuals who are chronically HIV-1–infected. Immunity to these viral antigens was not associated with increased Fab glycosylation levels, indicating that chronic antigen-stimulation as such does not lead to increased Fab glycosylation levels. Conclusions: These data indicate that in chronic but not acute B cell–mediated autoimmune diseases, disease-specific autoantibodies are enriched for Fab glycans